Experience

• • Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, in its Series F financing round and $60 million initial public offering.
  • Depository Trust & Clearing Corporation, a financial institution that helps markets grow and protect the security of the global financial system, in its investment into the £77.7M Series B financing round of Fnality.  

  • Editas Medicine, Inc., a clinical stage gene editing company, in multiple public offerings as well as general corporate governance and public reporting matters.
  • Flare Therapeutics, a biotechnology company leveraging the power of “switch sites” as druggable regions that hold the control for predictable and profound changes in DNA transcription and gene expression, in its $82 million Series A financing round and $125 million Series B financing.
  • PTC Therapeutics, a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines for patients with rare disorders, in its strategic financing collaboration with Blackstone for up to $1 billion in funding.
  • Rectify Pharmaceuticals, a developer of therapies to treat genetic disorders using small molecule correctors of ABC transporters, in its $96 million Series A financing round.
  • Volastra Therapeutics, a biotechnology company focused on developing novel therapies for patients with metastatic cancers, in its $20 million Series A financing round.
  • Preferred stock financings on behalf of multiple private company technology clients including Jebbit, Inc., Supply, Inc., and Electra Vehicles, Inc.
  • Various financial and investment institutions in numerous private company investments and financings, initial public offerings and follow-on public offerings.